-
Something wrong with this record ?
MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML
NSD. Larmonie, TCJM. Arentsen-Peters, A. Obulkasim, D. Valerio, E. Sonneveld, AA. Danen-van Oorschot, V. de Haas, D. Reinhardt, M. Zimmermann, J. Trka, A. Baruchel, R. Pieters, MM. van den Heuvel-Eibrink, CM. Zwaan, M. Fornerod,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
28892045
DOI
10.1038/onc.2017.293
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute blood genetics pathology MeSH
- Azacitidine analogs & derivatives pharmacology MeSH
- CpG Islands genetics MeSH
- Decitabine MeSH
- Child MeSH
- DNA (Cytosine-5-)-Methyltransferases metabolism MeSH
- Epigenesis, Genetic genetics MeSH
- Exons genetics MeSH
- Oncogene Proteins, Fusion genetics MeSH
- Nucleic Acid Hybridization methods MeSH
- Carcinogenesis genetics MeSH
- Infant MeSH
- Humans MeSH
- DNA Methylation drug effects genetics MeSH
- Adolescent MeSH
- Cell Line, Tumor MeSH
- Tumor Suppressor Proteins genetics MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Promoter Regions, Genetic genetics MeSH
- Gene Expression Regulation, Leukemic * MeSH
- Oligonucleotide Array Sequence Analysis methods MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
In acute myeloid leukemia (AML), specific genomic aberrations induce aberrant methylation, thus directly influencing the transcriptional programing of leukemic cells. Therefore, therapies targeting epigenetic processes are advocated as a promising therapeutic tool for AML treatment. However, to develop new therapies, a comprehensive understanding of the mechanism(s) driving the epigenetic changes as a result of acquired genetic abnormalities is necessary. This understanding is still lacking. In this study, we performed genome-wide CpG-island methylation profiling on pediatric AML samples. Six differentially methylated genomic regions within two genes, discriminating inv(16)(p13;q22) from non-inv(16) pediatric AML samples, were identified. All six regions had a hypomethylated phenotype in inv(16) AML samples, and this was most prominent at the regions encompassing the meningioma (disrupted in balanced translocation) 1 (MN1) oncogene. MN1 expression primarily correlated with the methylation level of the 3' end of the MN1 exon-1 locus. Decitabine treatment of different cell lines showed that induced loss of methylation at the MN1 locus can result in an increase of MN1 expression, indicating that MN1 expression is coregulated by DNA methylation. To investigate this methylation-associated mechanism, we determined the expression of DNA methyltransferases in inv(16) AML. We found that DNMT3B expression was significantly lower in inv(16) samples. Furthermore, DNMT3B expression correlated negatively with MN1 expression in pediatric AML samples. Importantly, depletion of DNMT3B impaired remethylation efficiency of the MN1 exon-1 locus in AML cells after decitabine exposure. These findings identify DNMT3B as an important coregulator of MN1 methylation. Taken together, this study shows that the methylation level of the MN1 exon-1 locus regulates MN1 expression levels in inv(16) pediatric AML. This methylation level is dependent on DNMT3B, thus suggesting a role for DNMT3B in leukemogenesis in inv(16) AML, through MN1 methylation regulation.
CHU de Paris Hôpital Robert Debré Paris France
Department of Pediatric Oncology Hematology Medical High School Hannover Germany
Dutch Childhood Oncology Group The Hague The Netherlands
Pediatric Hematology Oncology 2nd Medical School Charles University Prague Czech Republic
Princess Maxima Center for Pediatric Oncology Utrecht The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001193
- 003
- CZ-PrNML
- 005
- 20200121143905.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/onc.2017.293 $2 doi
- 035 __
- $a (PubMed)28892045
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Larmonie, N S D $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 245 10
- $a MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML / $c NSD. Larmonie, TCJM. Arentsen-Peters, A. Obulkasim, D. Valerio, E. Sonneveld, AA. Danen-van Oorschot, V. de Haas, D. Reinhardt, M. Zimmermann, J. Trka, A. Baruchel, R. Pieters, MM. van den Heuvel-Eibrink, CM. Zwaan, M. Fornerod,
- 520 9_
- $a In acute myeloid leukemia (AML), specific genomic aberrations induce aberrant methylation, thus directly influencing the transcriptional programing of leukemic cells. Therefore, therapies targeting epigenetic processes are advocated as a promising therapeutic tool for AML treatment. However, to develop new therapies, a comprehensive understanding of the mechanism(s) driving the epigenetic changes as a result of acquired genetic abnormalities is necessary. This understanding is still lacking. In this study, we performed genome-wide CpG-island methylation profiling on pediatric AML samples. Six differentially methylated genomic regions within two genes, discriminating inv(16)(p13;q22) from non-inv(16) pediatric AML samples, were identified. All six regions had a hypomethylated phenotype in inv(16) AML samples, and this was most prominent at the regions encompassing the meningioma (disrupted in balanced translocation) 1 (MN1) oncogene. MN1 expression primarily correlated with the methylation level of the 3' end of the MN1 exon-1 locus. Decitabine treatment of different cell lines showed that induced loss of methylation at the MN1 locus can result in an increase of MN1 expression, indicating that MN1 expression is coregulated by DNA methylation. To investigate this methylation-associated mechanism, we determined the expression of DNA methyltransferases in inv(16) AML. We found that DNMT3B expression was significantly lower in inv(16) samples. Furthermore, DNMT3B expression correlated negatively with MN1 expression in pediatric AML samples. Importantly, depletion of DNMT3B impaired remethylation efficiency of the MN1 exon-1 locus in AML cells after decitabine exposure. These findings identify DNMT3B as an important coregulator of MN1 methylation. Taken together, this study shows that the methylation level of the MN1 exon-1 locus regulates MN1 expression levels in inv(16) pediatric AML. This methylation level is dependent on DNMT3B, thus suggesting a role for DNMT3B in leukemogenesis in inv(16) AML, through MN1 methylation regulation.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a azacytidin $x analogy a deriváty $x farmakologie $7 D001374
- 650 _2
- $a karcinogeneze $x genetika $7 D063646
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a CpG ostrůvky $x genetika $7 D018899
- 650 _2
- $a DNA-(cytosin-5-)methyltransferasa $x metabolismus $7 D004248
- 650 _2
- $a metylace DNA $x účinky léků $x genetika $7 D019175
- 650 _2
- $a decitabin $7 D000077209
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a exony $x genetika $7 D005091
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a regulace genové exprese u leukemie $7 D015973
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a akutní myeloidní leukemie $x krev $x genetika $x patologie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a hybridizace nukleových kyselin $x metody $7 D009693
- 650 _2
- $a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $x metody $7 D020411
- 650 _2
- $a fúzní onkogenní proteiny $x genetika $7 D015514
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 650 _2
- $a nádorové supresorové proteiny $x genetika $7 D025521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Arentsen-Peters, T C J M $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Obulkasim, A $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Valerio, D $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Sonneveld, E $u Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
- 700 1_
- $a Danen-van Oorschot, A A $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a de Haas, V $u Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands.
- 700 1_
- $a Reinhardt, D $u Department of Pediatric Oncology/Hematology, Medical High School, Hannover, Germany.
- 700 1_
- $a Zimmermann, M $u Department of Pediatric Oncology/Hematology, Medical High School, Hannover, Germany.
- 700 1_
- $a Trka, J $u Pediatric Hematology/Oncology, 2nd Medical School, Charles University, Prague, Czech Republic.
- 700 1_
- $a Baruchel, A $u CHU de Paris-Hôpital Robert Debré, Paris, France.
- 700 1_
- $a Pieters, R $u Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a van den Heuvel-Eibrink, M M $u Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a Zwaan, C M $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Fornerod, M $u Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 773 0_
- $w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 37, č. 1 (2018), s. 107-115
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28892045 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20200121144242 $b ABA008
- 999 __
- $a ok $b bmc $g 1365094 $s 1039316
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 37 $c 1 $d 107-115 $e 20170911 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
- LZP __
- $a Pubmed-20190107
